Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Gene Therapy

• Publication date

  2006-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/sj.gt.3302800PMID 16724091
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles.

  2005cited by this paper
• Duchenne muscular dystrophy and steroids: pharmacologic treatment in the absence of effective gene therapy.

  2005cited by this paper
• Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells

  2004cited by this paper
• Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides.

  2004cited by this paper
• Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense.

  2004cited by this paper
• Longterm noninvasive ventilation in children and adolescents with neuromuscular disorders

  2003cited by this paper
• Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse

  2003cited by this paper
• Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients.

  2003cited by this paper
• ESEfinder: a web resource to identify exonic splicing enhancers

  2003cited by this paper
• Mfold web server for nucleic acid folding and hybridization prediction

  2003cited by this paper
• Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle.

  2003cited by this paper
• Advances in Duchenne muscular dystrophy gene therapy

  2003cited by this paper
• The muscular dystrophies.

  2002cited by this paper
• Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy

  2002cited by this paper
• Cationic lipid polymerization as a novel approach for constructing new DNA delivery agents.

  2001cited by this paper
• Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells.

  2001cited by this paper
• Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse.

  2001cited by this paper
• Exonic splicing enhancers: mechanism of action, diversity and role in human genetic diseases.

  2000cited by this paper
• Molecular mechanisms of action of antisense drugs.

  1999cited by this paper
• Use of the dog model for Duchenne muscular dystrophy in gene therapy trials.

  1997cited by this paper
• An explanation for the constitutive exon 9 cassette splicing of the DMD gene.

  1994cited by this paper
• Becker muscular dystrophy with onset after 60 years

  1994cited by this paper
• Analysis of the RNA-recognition motif and RS and RGG domains: conservation in metazoan pre-mRNA splicing factors.

  1993cited by this paper
• An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy.

  1992cited by this paper
• The homologue of the Duchenne locus is defective in X-linked muscular dystrophy of dogs

  1988cited by this paper
• Dystrophin: the protein product of the Duchenne muscular dystrophy locus.

  1987cited by this paper

• Molecular Bases of Myopathies and Their Impact on Clinical Practice: Advances and Future Perspectives

  2026cites this paper
• Cell-penetrating peptide-conjugated, splice-switching oligonucleotides mitigate the phenotype in BTK/Tec double deficient X-linked agammaglobulinemia model

  2025cites this paper
• Evolution and Breakthroughs in Exon Skipping and Splice Modulation: From Inception to Clinical Success.

  2025cites this paper
• Recent applications of RNA therapeutic in clinics.

  2024cites this paper
• Down syndrome and DYRK1A overexpression: relationships and future therapeutic directions

  2024cites this paper
• Induced alternative splicing an opportunity to study PCSK9 protein isoforms at physiologically relevant concentrations

  2023cites this paper
• Enhancing the Effectiveness of Oligonucleotide Therapeutics Using Cell-Penetrating Peptide Conjugation, Chemical Modification, and Carrier-Based Delivery Strategies

  2023cites this paper
• Functionalization of acyclic xenonucleic acid with modified nucleobases

  2023cites this paper
• Control of backbone chemistry and chirality boost oligonucleotide splice switching activity

  2022cites this paper
• Antisense oligonucleotides targeting exon 11 are able to partially rescue the Neurofibromatosis Type 2 phenotype in vitro

  2022cites this paper
• Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype in vitro

  2022cites this paper
• Correction of DMD in human iPSC-derived cardiomyocytes by base-editing-induced exon skipping

  2022cites this paper
• Comparison of dystrophin expression following gene editing and gene replacement in an aged preclinical DMD animal model.

  2022cites this paper
• Assessment of Respiratory Motor Units in the mdx Mouse Model of Duchenne Muscular Dystrophy

  2022cites this paper
• Antisense Oligonucleotide Therapy for the Nervous System: From Bench to Bedside with Emphasis on Pediatric Neurology

  2022cites this paper
• Analysis of Merlin-e11 phenotype recovery : an actin immunocytochemistry assay

  2022cites this paper
• Intrinsically Disordered Proteins, Structural and Functional Dynamics

  2022cites this paper
• Analysis of Merlin-e11 phenotype recovery : an actin immunocytochemistry assay

  2022cites this paper
• Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular Dystrophy

  2021cites this paper
• Muscular dystrophy: Experimental animal models and therapeutic approaches (Review)

  2021cites this paper
• Immortalized Canine Dystrophic Myoblast Cell Lines for Development of Peptide-Conjugated Splice-Switching Oligonucleotides

  2021cites this paper
• Animal models for researching approaches to therapy of Duchenne muscular dystrophy

  2021cites this paper
• Polyglutamine Ataxias: Our Current Molecular Understanding and What the Future Holds for Antisense Therapies

  2021cites this paper
• Antisense Oligonucleotide Therapy to Correct CFTR Function in People with Cystic Fibrosis

  2021cites this paper
• Pharmacology and toxicology of eteplirsen and SRP-5051 for DMD exon 51 skipping: an update

  2021cites this paper
• Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation

  2021cites this paper
• Emerging Oligonucleotide Therapeutics for Rare Neuromuscular Diseases

  2021cites this paper
• Gene Therapies for Axonal Neuropathies: Available Strategies, Successes to Date, and What to Target Next.

  2020cites this paper
• Alternative Splicing in the Nuclear Receptor Superfamily Expands Gene Function to Refine Endo-Xenobiotic Metabolism

  2020cites this paper
• RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges

  2020cites this paper
• Advances in oligonucleotide drug delivery

  2020cites this paper
• Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development

  2020cites this paper
• Alternative Splicing in the Nuclear Receptor Superfamily Redirects Human Metabolic Homeostasis

  2020cites this paper
• Splice modulating antisense oligonucleotides restore some acid-alpha-glucosidase activity in cells derived from patients with late-onset Pompe disease

  2020cites this paper
• Splicing mutations in inherited retinal diseases.

  2020cites this paper
• In Vitro Validation of Phosphorodiamidate Morpholino Oligomers

  2019cites this paper
• Reduction of integrin alpha 4 activity through splice modulating antisense oligonucleotides

  2019cites this paper
• Pathological Issues in Dystrophinopathy in the Age of Genetic Therapies.

  2019cites this paper
• Targeting RyR Activity Boosts Antisense Exon 44 and 45 Skipping in Human DMD Skeletal or Cardiac Muscle Culture Models

  2019cites this paper
• Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases

  2019cites this paper
• Removal of the Polyglutamine Repeat of Ataxin-3 by Redirecting pre-mRNA Processing

  2019cites this paper
• Alternative splicing of the vitamin D receptor modulates target gene expression and promotes ligand‐independent functions

  2019cites this paper
• Multiple Exon Skipping in the Duchenne Muscular Dystrophy Hot Spots: Prospects and Challenges

  2018cites this paper
• Exon Skipping and Inclusion Therapies

  2018cites this paper
• Handbook of Laboratory Animal Science Animal Models

  2018cites this paper
• Molecular Basis of Resilience

  2018cites this paper
• Invention and Early History of Exon Skipping and Splice Modulation.

  2018cites this paper
• Splice-Switching Oligonucleotides

  2018cites this paper
• Animal Models for Tropical Parasitic Diseases

  2018cites this paper
• (R‐X‐R)4‐Motif Peptides Containing Conformationally Constrained Cyclohexane‐Derived Spacers: Effect on Cellular Uptake

  2017cites this paper
• Using Morpholinos to Control Gene Expression

  2017cites this paper
• Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues

  2017cites this paper
• Alternative Splicing in the Cytochrome P450 Superfamily Expands Protein Diversity to Augment Gene Function and Redirect Human Drug Metabolism

  2017influential citation
• Gene therapies that restore dystrophin expression for the treatment of Duchenne muscular dystrophy

  2016cites this paper
• Antisense oligonucleotide development for the treatment of muscular dystrophies

  2016cites this paper
• Frontiers in Skeletal Muscle Wasting, Regeneration and Stem Cells

  2016cites this paper
• Human iPSC-derived cardiomyocytes as platforms for cardiac disease modeling, therapeutic discovery and safety pharmacology

  2016cites this paper
• Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

  2016cites this paper
• Dystrophin and the two related genetic diseases, Duchenne and Becker muscular dystrophies.

  2015cites this paper
• Duchenne Muscular Dystrophy Gene Therapy in the Canine Model

  2015cites this paper
• The emperor's new dystrophin: finding sense in the noise.

  2015cites this paper
• Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy

  2015cites this paper
• Bi-specific splice-switching PMO oligonucleotides conjugated via a single peptide active in a mouse model of Duchenne muscular dystrophy

  2014influential citation
• Design and Application of Bispecific Splice-Switching Oligonucleotides

  2014cites this paper
• Antisense-Mediated Exon Skipping for Duchenne Muscular Dystrophy

  2014cites this paper
• Molecular targets to treat muscular dystrophies.

  2014cites this paper
• Skipping Multiple Exons of Dystrophin Transcripts Using Cocktail Antisense Oligonucleotides

  2014influential citation
• Antisense Oligonucleotide Induction of Progerin in Human Myogenic Cells

  2014cites this paper
• Peptide Conjugation of 2′-O-methyl Phosphorothioate Antisense Oligonucleotides Enhances Cardiac Uptake and Exon Skipping in mdx Mice

  2014cites this paper
• Antisense Oligonucleotide : Basic Concept and its Therapeutic Application * Corresponding

  2014cites this paper
• Geneand cell-based therapy of muscle system hereditary disorders: state-of-art

  2014cites this paper
• New developments in the use of gene therapy to treat Duchenne muscular dystrophy

  2014cites this paper
• Molecular and cell-based therapies for muscle degenerations: a road under construction

  2014cites this paper
• Chapter 125 – Muscular Dystrophies

  2013cites this paper
• Antisense suppression of donor splice site mutations in the dystrophin gene transcript

  2013influential citation
• Disease‐Specific Models to Enhance Pediatric Drug Development

  2013cites this paper
• Targeting RNA splicing for disease therapy

  2013cites this paper
• Resveratrol as a Novel Therapeutic Agent for Treating Duchenne Muscular Dystrophy

  2013cites this paper
• Animal Models for Tropical Parasitic Diseases

  2013cites this paper
• Targeting RNA splicing for disease

  2013cites this paper
• Rescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in mice

  2013cites this paper
• Development of Multiexon Skipping Antisense Oligonucleotide Therapy for Duchenne Muscular Dystrophy

  2013influential citation
• Antisense Therapy in Neurology

  2013cites this paper
• Genetic Therapeutic Approaches for Duchenne Muscular Dystrophy

  2012cites this paper
• Exon Skipping

  2012cites this paper
• Overview on DMD exon skipping.

  2012cites this paper
• Multiple exon skipping strategies to by-pass dystrophin mutations

  2012cites this paper
• Optimizing antisense oligonucleotides using phosphorodiamidate morpholino oligomers.

  2012cites this paper
• Antisense-mediated myostatin downregulation by destructive exon skipping using 2'O-methyl RNA and morpholino oligomers in skeletal muscle cells and animal models

  2012cites this paper
• Long-term restoration of cardiac dystrophin expression in golden retriever muscular dystrophy following rAAV6-mediated exon skipping.

  2012cites this paper
• Antisense oligonucleotide-mediated exon skipping for Duchenne muscular dystrophy: progress and challenges.

  2012cites this paper
• Cell-penetrating peptides for the delivery of nucleic acids

  2012cites this paper
• Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping.

  2012cites this paper
• AON-Mediated Exon Skipping for Duchenne Muscular Dystrophy

  2012cites this paper
• Cell-penetrating peptides; chemical modification, mechanism of uptake and formulation development

  2012influential citation
• Exon skipping for nonsense mutations in Duchenne muscular dystrophy: too many mutations, too few patients?

  2012cites this paper
• Extensive and Prolonged Restoration of Dystrophin Expression with Vivo-Morpholino-Mediated Multiple Exon Skipping in Dystrophic Dogs

  2012cites this paper
• Bodywide skipping of exons 45–55 in dystrophic mdx52 mice by systemic antisense delivery

  2012cites this paper
• Functional delivery of DNAzyme with iron oxide nanoparticles for hepatitis C virus gene knockdown.

  2012cites this paper
• Long-term Exon Skipping Studies With 2′-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models

  2012cites this paper